Asset
DAROVASERTIB
IDEAYA BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05907954 | phase2 | active_not_recruiting | 2023-07-03 | 2027-04-30 | IDEAYA Biosciences | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
| NCT05987332 | phase2_3 | active_not_recruiting | 2023-10-31 | 2027-01-15 | IDEAYA Biosciences | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| NCT07015190 | phase3 | recruiting | 2026-01-25 | 2030-10-01 | IDEAYA Biosciences | Neoadjuvant Darovasertib in Primary Uveal Melanoma |
| NCT07804186 | phase3 | recruiting | 2026-09-01 | 2034-03-01 | IDEAYA Biosciences | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma |
| NCT03947385 | phase1_2 | recruiting | 2019-06-28 | 2027-01-29 | IDEAYA Biosciences | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
FDA applications (0)
This company has no applications containing this asset.